SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +22.2% ·
share flow -14.1% ·
net new positions +18.2%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.03M | -26.1% | $25.55M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.26M | +1.8% | $15.86M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.26M | +1.8% | $15.86M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Millennium Management ✦ | 807.04K | -14.1% | $10.15M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 801.29K | -0.5% | $10.08M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 801.29K | -0.5% | $10.08M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Marshall Wace ✦ | 156.63K | +196.1% | $1.97M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 156.63K | +196.1% | $1.97M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 131.78K | -19.3% | $1.66M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 131.78K | -19.3% | $1.66M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 33.80K | -56.0% | $425,166 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 21.76K | +9.2% | $274,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 13.03K | New | $163,905 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 11.12K | New | $139,839 | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 11.12K | New | $139,839 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 11.12K | New | $139,839 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 11.12K | New | $139,839 | 0.0% | New | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 11.12K | New | $139,839 | 0.0% | New | 1 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 10.77K | -89.0% | $135,499 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Gotham Asset Management | $163,905 | 0.0% |
| AQR Capital Management | $139,839 | 0.0% |
| AQR Capital Management | $139,839 | 0.0% |
| AQR Capital Management | $139,839 | 0.0% |
| AQR Capital Management | $139,839 | 0.0% |
| AQR Capital Management | $139,839 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 201 holders, 92.94M shares, $730.00M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.